Regional overviews

celebrating 20 years Latin America

STATISTICS  
Number of products launched: 11 (2017: 26)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD424 million
3 – 5 years USD298 million
Number of product recalls: 2 (2017: 1)
Average staff turnover: 22,8% (2017: 29,5%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals. Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semi-solids and liquids.

KEY COUNTRIES

Brazil, Chile, Colombia, Ecuador, Mexico

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Commercial Pharmaceuticals 2 929 2 577 14
Regional Brands 1 306 1 116 17
Anaesthetics 762 571 33
Thrombosis 71 87 (18)
High Potency & Cytotoxics 790 803 (2)
Nutritionals 1 290 1 414 (9)
Manufacturing – FDP 12 100
Total 4 231 3 991 6

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture

 
  • The Spanish Latin American private pharmaceutical sector grew 8,9% to USD25,2 billion for the year to 30 June 2018 as per IMS.
  • The Brazilian private pharmaceutical sector grew 5,4% and was valued by IMS at USD30,0 billion for the year to 30 June 2018.
Source: June 2018 IMS